Wall Street Zen Downgrades Avalo Therapeutics (NASDAQ:AVTX) to Sell

Avalo Therapeutics (NASDAQ:AVTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts also recently issued research reports about the stock. Wedbush dropped their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Leerink Partners started coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective for the company. Bank of America initiated coverage on Avalo Therapeutics in a research report on Friday, June 12th. They issued a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings downgraded Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reduced their target price on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.10.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $18.32 on Friday. Avalo Therapeutics has a 1-year low of $8.29 and a 1-year high of $24.27. The business has a fifty day moving average price of $17.26 and a 200-day moving average price of $16.29. The company has a market capitalization of $982.50 million, a PE ratio of -4.19 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, sell-side analysts anticipate that Avalo Therapeutics will post -2.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares in the company, valued at $931,968. This trade represents a 2.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently bought and sold shares of AVTX. Orbimed Advisors LLC increased its position in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after buying an additional 382,300 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in Avalo Therapeutics by 27.6% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Caligan Partners LP raised its stake in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $10,390,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.